{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:32:14Z","timestamp":1782732734643,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ygyno.2015.03.008","type":"journal-article","created":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T08:21:41Z","timestamp":1426926101000},"page":"392-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian\/primary peritoneal\/fallopian tube cancers: A retrospective review"],"prefix":"10.1016","volume":"137","author":[{"given":"Dana M.","family":"Roque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S.","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Arin","family":"Silasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendelin K.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2015.03.008_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.ygyno.2015.03.008_bb0010","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2015.03.008_bb0015","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2001.19.20.4048","article-title":"Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study","volume":"19","author":"Hoskins","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.03.008_bb0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2006.03.019","article-title":"Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study","volume":"103","author":"Sovak","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2015.03.008_bb0025","first-page":"167","article-title":"Comparison of epothilone and taxol binding in yeast tubulin using molecular modeling","volume":"3","author":"Akbari","year":"2011","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-008-0724-8","article-title":"Preclinical discovery of ixabepilone, a highly active antineoplastic agent","volume":"63","author":"Lee","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0035","author":"Federal Drug Administration"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0040","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: a Gynecologic Oncology Group Trial 129-P","volume":"27","author":"Dizon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2009.24.1455","article-title":"Phase II clinical trial of ixabepilone inpatients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"28","author":"De Geest","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0050","first-page":"3776","article-title":"Taxane-induced apoptosis decompresses blood vessels and lowers interstitial pressure in tumors: clinical implications","volume":"59","author":"Griffin-Etienne","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0055","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0060","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0065","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2015.03.008_bb0070","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"24 Suppl. 3","key":"10.1016\/j.ygyno.2015.03.008_bb0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.SABCS-09-206","article-title":"Anti-angiogenic synergy with ixabepilone: translation of preclinical studies to the clinical setting","volume":"69","author":"Lee","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e15526","article-title":"Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer","volume":"30","author":"Roque","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0095","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0100","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0105","author":"American Society of Clinical Oncology"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","author":"Rustin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijgo.2007.11.004","article-title":"History of the FIGO cancer staging system","volume":"101","author":"Odicino","year":"2008","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"FIGO","year":"2009","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0135","author":"U.S. Department of Health and Human Services"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0140","series-title":"Package insert prescribing information","author":"Avastin","year":"2014"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0145","first-page":"851","article-title":"Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"19","author":"Kabbinvar","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0150","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus 5FU\/leucovorin in firstline metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinvar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0155","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2014.07.101","article-title":"A phase II evaluation of ixabepilone in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"135","author":"Duska","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0165","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2009.08.032","article-title":"Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer","volume":"115","author":"Hurt","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"18","key":"10.1016\/j.ygyno.2015.03.008_bb0170","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Laurraine","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2015.03.008_bb0175","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2015.03.008_bb0180","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0185","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0190","author":"US Department of Health and Human Services"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0195","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-013-2552-8","article-title":"A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer","volume":"139","author":"Rugo","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0200","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3weeksfor advanced ovarian cancer: a phase 3, open-label, randomized controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2015.03.008_bb0205","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.lba5501","volume":"31","author":"Pignata","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.cra1008","article-title":"Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer","volume":"31","author":"Budd","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0220","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.008_bb0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2015.03.008_bb0230","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2015.03.008_bb0235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line therapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2015.03.008_bb0240","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/IGC.0b013e3181a12eb9","article-title":"Is there a taxane-free interval that predicts response to taxanes as a later-line treatment for recurrent ovarian or primary peritoneal cancer?","volume":"19","author":"McCourt","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 10","key":"10.1016\/j.ygyno.2015.03.008_bb0245","doi-asserted-by":"crossref","first-page":"x53","DOI":"10.1093\/annonc\/mdt472","article-title":"Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease","volume":"24","author":"Monk","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.03.008_bb0250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2014.10.020","article-title":"A cost-utility analysis of NRG Oncology\/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer","volume":"136","author":"Cohn","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2015.03.008_bb0255","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1634\/theoncologist.2013-0322","article-title":"Bevacizumab in treatment of high-risk ovarian cancer: a cost-effectiveness analysis","volume":"19","author":"Chan","year":"2014","journal-title":"Oncologist"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T02:37:21Z","timestamp":1598841441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815006836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0090825815006836"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian\/primary peritoneal\/fallopian tube cancers: A retrospective review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}